Full history for every metric is available with a Kvantra account
Kadimastem Ltd (KDST.TA)
Key financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ILS m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | ILS m | -7 | -5 | |||||
| Net profit | ILS m | -25 | -22 | -26 | -23 | -12 | -27 | - |
| EPS reported | ILS | -6.33 | - | |||||
| Operating cashflow per share | ILS | -0.66 | -0.58 | |||||
| Capex per share | ILS | 0.01 | 0.00 | |||||
| FCF per share | ILS | -0.66 | -0.58 | |||||
| Free cash flow | ILS m | -3 | -0 | |||||
| Net debt | ILS m | 26 | 8 | |||||
| Book value equity | ILS m | -29 | -51 | |||||
| Book value per share | ILS | -6.95 | -11,769 | |||||
| Number of shares | m | 4.19 | 0 | |||||
| DPS (TTM paid) | ILS | 0.00 | 0.00 |
Financial summary
Financials in ILS| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.87 | -2.47 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -19.68 | -58,289.29 | |||||
| EV/EBITDA LTM | x | -12.96 | -16,304.57 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -48.60% | -33.40% | |||||
| FCF Yield | % | -5.08% | -0.00% | |||||
| Quality | ||||||||
| ROE | % | 91.10% | 0.08% | |||||
| ROIC | % | 680.93% | 10.69% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.10 | -0.00 | |||||
| Net Debt/EBITDA | x | -4.16 | -1,576.51 | |||||
| EBIT/Net interest | x | -38.40 | -0.13 | |||||
| Net debt/market cap | % | 47.23% | 6.03% | |||||
| Net debt/Equity | x | -0.89 | -0.15 | |||||
| Gross debt/equity | x | -0.97 | -0.17 | |||||
Company overview
Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kadimastem Ltd (KDST.TA)
Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free